Skip to main content
Premium Trial:

Request an Annual Quote

Robert Millman, Elizabeth Stoner, Alain Beaudet, Guangping Gao, David Slye, Shobha Parthasarathi, David Ramsay

Millman, Stoner Join MPM Capital’s Boston Office
Life science investment firm MPM Capital said last week that Robert Millman and Elizabeth Stoner have joined as executive partners in MPM’s Boston office.
Millman was most recently chief IP counsel for Alnylam Pharmaceuticals. Prior to Alnylam, he served as the chief IP counsel at Infinity Pharmaceuticals for three years. From 1999 to 2002, he was chief IP counsel at Celera Genomics. Prior to that, he was patent counsel at Millennium Pharmaceuticals, an associate at Morrison and Foerster, and a patent agent at Sterne, Kessler Goldstein and Fox.
Millman received a JD from the Washington College of Law at American University, an MS in genetics from Washington State University, and a BS in biochemistry from the University of California, Riverside.
Stoner joins MPM after 22 years at Merck Research Laboratories, where she most recently served as senior vice president of global clinical development operations. Prior to Merck, she was an assistant professor of pediatrics at Cornell University Medical College.
Stoner received a BS in chemistry from Ottawa University, Kansas, an MS in chemistry from the State University of New York at Stony Brook, and an MD from Albert Einstein College of Medicine.

Canadian Institutes of Health Research Names Alain Beaudet President
The Canadian Institutes of Health Research has named Montreal physician Alain Beaudet as its new president, effective July 1.
Beaudet is currently president and CEO of the Québec government's medical research funding agency, called Fonds de La Recherche en Santé Québec, or FRSQ. He takes over for acting president Pierre Chartrand, who has been filling in since CIHR head Alan Bernstein resigned in October to serve as executive director of the Global HIV Vaccine Enterprise.
Beaudet holds a medical degree and a PhD in neuroscience from the Université de Montréal. He did postdoctoral training at the Centre d'études nucléaires in Saclay, France, and the University of Zurich's Brain Research Institute in Switzerland.
He taught in McGill University's Neurology-Neurosurgery and Anatomy-Cell Biology departments, and was assistant director of research at the Montreal Neurological Institute. He also served as president of the Canadian Association for Neuroscience from 1995 to 1997.

UMass Med School Taps Gao to Head Gene Therapy Center

The University of Massachusetts Medical School has tapped Guangping Gao, a researcher from the University of Pennsylvania School of Medicine, as founding director of the UMMS Gene Therapy Center, one of three UMass research “clusters” funded under Gov. Deval Patrick’s $1 billion life science initiative.

Gao, an expert in adeno-associated viruses, joins UMMS from a position as director of the Vector Program in the Gene Therapy Program in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine.
Gao will also direct the UMass Medical School - China Translational Research Initiative, a collaboration with Tsinghua University in Beijing to develop new drugs and medical devices.
A graduate of Florida International University, Gao received his doctoral degree in biomedical sciences, and completed his post-doctoral fellowship in gene therapy at the Institute for Human Gene Therapy at the University of Pennsylvania.

Jones Lang LaSalle Names David Slye New England Regional Director
Real estate services firm Jones Lang LaSalle has named David Slye as New England regional director.
Slye, formerly managing director of the company’s business development team, will oversee the New England office.
Slye has worked at Jones Lang LaSalle and the former Spaulding & Slye for 11 years. He is a graduate of Babson College, and currently sits on the board of trustees of FCD Educational Services.

NC Biotech Center Taps Parthasarathi as Tech Development Director
Shobha Parthasarathi has joined the North Carolina Biotechnology Center as technology development director in NCBC’s Business and Technology Development unit.  
Parthasarathi was previously a senior researcher and manager at Millennium Pharmaceuticals, where she conducted drug discovery research, evaluated technologies, and developed in-house expertise for multiple therapeutic groups.
Parthasarathi succeeds Rob Lindberg, who has become director of the NCBC’s Business Acceleration & Technology Out-licensing Network, or BATON, program.

Ramsay Receives Greater Baltimore Region’s President’s Award
David Ramsay, president of the University of Maryland, Baltimore, was among several winners of the 2008 Greater Baltimore Region Bioscience Awards announced last week.
Ramsay, the recipient of the President’s Award, has “championed the growth of biomedical research and technology transfer at UMB, where biotech research has grown by 500 percent since 1994,” the Greater Baltimore Committee said in a statement.
Ramsay has also been leading development of the UMB BioPark in west Baltimore, which has grown to 340,000 square feet of research space and created 200 biotech jobs over the last five years, the committee said.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.